Supramolecular purification of mono-adamantane mixtures

Clara Sabrià, Tània Pèlachs, Inhar Imaz, Daniel Maspoch, Ferran Feixas, Xavi Ribas

Abstract read

In one paragraph

Article in Chemical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Clara SabriàInstitut de Química Computacional i Catàlisi (IQCC), Departament de Química, Universitat de Girona Campus Montilivi 17003 Girona Catalonia Spain ferran.feixas@udg.edu xavi.ribas@udg.edu.

Tània PèlachsInstitut de Química Computacional i Catàlisi (IQCC), Departament de Química, Universitat de Girona Campus Montilivi 17003 Girona Catalonia Spain ferran.feixas@udg.edu xavi.ribas@udg.edu.

Inhar ImazCatalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC, The Barcelona Institute of Science and Technology Campus UAB, Bellaterra 08193 Catalonia Spain.

Daniel MaspochCatalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC, The Barcelona Institute of Science and Technology Campus UAB, Bellaterra 08193 Catalonia Spain.ORCID https://orcid.org/0000-0003-1325-9161

Ferran FeixasInstitut de Química Computacional i Catàlisi (IQCC), Departament de Química, Universitat de Girona Campus Montilivi 17003 Girona Catalonia Spain ferran.feixas@udg.edu xavi.ribas@udg.edu.ORCID https://orcid.org/0000-0001-5147-0000

Xavi RibasInstitut de Química Computacional i Catàlisi (IQCC), Departament de Química, Universitat de Girona Campus Montilivi 17003 Girona Catalonia Spain ferran.feixas@udg.edu xavi.ribas@udg.edu.ORCID https://orcid.org/0000-0002-2850-4409

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The adamantane (Ad) core is widely used in pharmaceuticals, where it is regarded as a lipophilic "bullet" that enhances the bioactivity of Ad-bearing drugs. Despite its prevalence, little is known about its precise recognition modes within confined enzymatic active sites, and effective chromatographic strategies for the purification of mixtures of Ad derivatives remain limited. Herein, we report the supramolecular purification of mono-adamantane mixtures through the development of three-shell supramolecular Matryoshka assemblies, featuring an adamantane-cycloparaphenylene (CPP) host-guest adduct encapsulated within a tetragonal prismatic nanocage. This three-shell architecture operates

Identifiers

PMID42273546

DOI10.1039/d6sc02321e

PMCPMC13248019

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.